# Topspin Consumer Partners

> Topspin Consumer Partners is a VC fund backing Biotechnology and Health Care. See 51 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Roslyn Heights, United States
- Total investments: 51
- Last investment: Jan 2022
- Lead investor: 33%
- Fund size: $205M
- Last fund: Jun 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/503127?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A503127%2Cidx%3A1-2-2%2CtarId%3A1442506059104%2Ctas%3ATopspin%20Partners
- Website: http://www.topspinpartners.com

Topspin Consumer Partners is a private equity firm that specializes in growing branded consumer products and services companies. With a team that has worked together for many years, Topspin follows a partnership approach aimed at driving enterprise value. The firm focuses on helping companies enhance their market presence, profitability, andoverall performance through strategic investments and operational improvements. Topspin Consumer Partners has a history of engaging with companies across various consumer sectors, providing them with the necessary resources and expertise to achieve their growth objectives.

## Contacts

5 contacts available for Topspin Consumer Partners. Shizune tracks 9 team members at Topspin Consumer Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/topspin-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 31% |
| Health Care | 12 | 24% |
| Therapeutics | 7 | 14% |
| Pharmaceutical | 7 | 14% |
| Medical | 5 | 10% |

55 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 11 | 22% |
| Series B | 10 | 20% |
| Funding Round | 6 | 12% |
| Series D | 5 | 10% |
| Series A | 4 | 8% |

12 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Stephen Lebowitz | Managing Director & Co-Founder | 2 | https://shizune.co/investors/profile/steve-lebowitz-aad8 |
| Ekta Sharma | Principal | 0 | https://shizune.co/investors/profile/ekta-sharma |
| Leigh J. Randall | Managing Partner | 3 | https://shizune.co/investors/profile/leigh-j-randall |
| Leo Guthart | Managing Partner | 2 | https://shizune.co/investors/profile/leo-guthart |
| Ojas Vahia | Partner | 2 | https://shizune.co/investors/profile/ojas-vahia |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mission Product Holdings | MISSION is the first and only line of Athlete-Engineered products designed to enhance performance intraining and competition. Launched in 2009, MISSION Athletecare has quickly become a driving force of innovation in the sports industry uniquely focused on products that help athletes prepare, perform and rehab from competition. |  | Private Equity | Jan 11, 2022 |  |
| Coop Home Goods | Coop provides comforters, mattress pads and protectors, bedding sets, pet beds, bed pillows, support pillows, pillow accessories, pillow sets, and throw pillows. Their customers' inquiries are addressed through phone, email, and online applications. |  | Private Equity | Aug 17, 2021 |  |
| SportPet | SportPet is a seasoned manufacturer and marketer of branded and private label pet products. |  | Private Equity | Aug 10, 2021 |  |
| reCommerce | reCommerce is a full-service brand agency that assists international brands in optimizing their Amazon presence and increasing sales. |  | Venture - Series Unknown | May 28, 2020 |  |
| Codagenix | Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchersto invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well. | $20M | Series B | Jan 13, 2020 |  |
| PMV Pharmaceuticals | PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. | $62M | Series C | Nov 13, 2019 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $15.7M |  | Sep 18, 2019 |  |
| ORIC Pharmaceuticals | ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $55M | Series D | Aug 09, 2019 |  |
| Rapt Therapeutics | RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development. | $37M | Series C | Jun 19, 2019 |  |
| Celmatix | Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” RSTK program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation ofinterventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. | $6.5M |  | Apr 01, 2019 |  |

10 of 51 investments shown.

## Co-investors
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 11 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 6 deals together
- [Action Potential Venture Capital](https://shizune.co/investors/profile/action-potential-venture-capital) — VC Fund, 3 deals together
- [Boston Scientific](https://shizune.co/investors/profile/boston-scientific) — VC Fund, 3 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 3 deals together
- [Euclidean Capital](https://shizune.co/investors/profile/euclidean-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Topspin Consumer Partners invest in?

Topspin Consumer Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 51 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Topspin Consumer Partners?

Public channels for Topspin Consumer Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Topspin Consumer Partners?

The team at Topspin Consumer Partners includes Stephen Lebowitz (Managing Director & Co-Founder), Ekta Sharma (Principal) and Leigh J. Randall (Managing Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co